biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

# Pathogenesis and Novel Diagnostic in Juvenile Idiopathic Arthritis

Guest Editor:

**Prof. Dr. Katarzyna Winsz-Szczotka**
Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Sosnowiec, Poland

Deadline for manuscript submissions:
**closed (31 December 2022)**

## Message from the Guest Editor

The term 'juvenile idiopathic arthritis' (JIA) defines a heterogeneous collection of autoimmune or autoinflammatory forms of chronic arthritis with onset in childhood, with origins that are not yet entirely understood.

There are no pathognomonic symptom or examination findings for JIA, and the diagnosis is made by exclusion and differentiation. JIA that is diagnosed too late or treated poorly treated may contribute to the disability of an afflicted child, due to disturbances in the structure and function of the osteoarticular system. Hence, prompt detection of structural disorders of articular cartilage would allow clinicians to initiate appropriate therapies, which is essential for the course of the arthropathy in question. Too late application of appropriate treatment, resulting from the lack of specific diagnostic biomarkers, may result in the perpetuation of pathological changes in the motor system in patients, or the development of systemic disorders, especially in those with high disease activity who require an aggressive therapy.

# biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI


## Editor-in-Chief


**Prof. Dr. Felipe Fregni**

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA


## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us


*Biomedicines* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI